These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 10503965)

  • 21. Effect of Y-24180, an antagonist at platelet-activating factor (PAF) receptors, on IgE-mediated cutaneous reactions in mice.
    Yamaguchi S; Tomomatsu N; Kagoshima M; Okumoto T; Komatsu H
    Inflamm Res; 1998 Dec; 47(12):506-11. PubMed ID: 9892046
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PAF-receptors on eosinophils: identification with a novel ligand, [3H]WEB 2086.
    Ukena D; Krogel C; Dent G; Yukawa T; Sybrecht G; Barnes PJ
    Biochem Pharmacol; 1989 May; 38(10):1702-5. PubMed ID: 2543419
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of Y-24180, a receptor antagonist to platelet-activating factor (PAF), on allergic cutaneous reactions in actively sensitized mice.
    Yamaguchi S; Tomomatsu N; Komatsu H
    Inflamm Res; 2000 Nov; 49(11):584-90. PubMed ID: 11131298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
    Herbert JM; Bernat A; Valette G; Gigo V; Lale A; LaPlace MC; Lespy L; Savi P; Maffrand JP; Le Fur G
    J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulatory role of protein kinase C on the signal transduction pathway utilized by platelet-activating factor in eosinophil activation.
    Kroegel C; Giembycz MA; Matthys H; Westwick J; Barnes PJ
    Am J Respir Cell Mol Biol; 1994 Nov; 11(5):593-9. PubMed ID: 7946388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of the platelet-activating factor receptor antagonist WEB 2086 on whole blood coagulation and fibrinolysis in a thromboelastography assay.
    Dambisya YM; Lee TL; Hussaini IM
    Blood Coagul Fibrinolysis; 1995 Dec; 6(8):733-7. PubMed ID: 8825223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suppressive effects of Y-24180, a receptor antagonist to platelet activating factor (PAF), on antigen-induced asthmatic responses in guinea pigs.
    Kagoshima M; Tomomatsu N; Iwahisa Y; Yamaguchi S; Matsuura M; Kawakami Y; Terasawa M
    Inflamm Res; 1997 Apr; 46(4):147-53. PubMed ID: 9137994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of platelet activating factor receptor antagonists on intracellular platelet activating factor function in neutrophils.
    Koike H; Imanishi N; Natsume Y; Morooka S
    Eur J Pharmacol; 1994 Nov; 269(3):299-309. PubMed ID: 7895770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation by IL-5 of expression of functional platelet-activating factor receptors on human eosinophils.
    Kishimoto S; Shimadzu W; Izumi T; Shimizu T; Fukuda T; Makino S; Sugiura T; Waku K
    J Immunol; 1996 Nov; 157(9):4126-32. PubMed ID: 8892648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel effect of Y-24180, a presumed specific platelet-activating factor receptor antagonist, on Ca2+ levels and growth of human osteosarcoma cells.
    Jan CR; Chao YY
    Pharmacol Res; 2005 Mar; 51(3):189-95. PubMed ID: 15661567
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Platelet-activating factor (PAF) receptor-mediated calcium mobilization and phosphoinositide turnover in neurohybrid NG108-15 cells: studies with BN50739, a new PAF antagonist.
    Yue TL; Gleason MM; Gu JL; Lysko PG; Hallenbeck J; Feuerstein G
    J Pharmacol Exp Ther; 1991 Apr; 257(1):374-81. PubMed ID: 1850473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cellular adhesion is required for effector functions of human eosinophils via G-protein coupled receptors.
    Fujiu T; Kato M; Kimura H; Tachibana A; Suzuki M; Nako Y; Morikawa A
    Ann Allergy Asthma Immunol; 2002 Jul; 89(1):90-8. PubMed ID: 12141728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Agonist-induced up-regulation of platelet-activating factor receptor messenger RNA in human monocytes.
    Shirasaki H; Adcock IM; Kwon OJ; Nishikawa M; Mak JC; Barnes PJ
    Eur J Pharmacol; 1994 Jul; 268(2):263-6. PubMed ID: 7957648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative assessment of increased airway microvascular permeability to 125I-labelled plasma fibrinogen induced by platelet activating factor and bradykinin.
    Pedersen KE; Rigby PJ; Goldie RG
    Br J Pharmacol; 1991 Sep; 104(1):128-32. PubMed ID: 1664758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-lasting inhibitory activity of the hetrazepinic BN 50730 on exudation and cellular alterations evoked by PAF and LPS.
    Pires AL; e Silva PM; Pasquale C; Castro-Faria-Neto HC; Bozza PT; Cordeiro RS; Rae GA; Braquet P; Lagente V; Martins MA
    Br J Pharmacol; 1994 Nov; 113(3):994-1000. PubMed ID: 7858896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological characterization of a receptor for platelet-activating factor on guinea pig peritoneal macrophages using [3H]apafant, a selective and competitive platelet-activating factor antagonist: evidence that the noncompetitive behavior of apafant in functional studies relates to slow kinetics of dissociation.
    Ring PC; Seldon PM; Barnes PJ; Giembycz MA
    Mol Pharmacol; 1993 Feb; 43(2):302-12. PubMed ID: 8381515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential actions of platelet-activating factor (PAF) receptor antagonists on the vasodilator and vasoconstrictor effects of PAF in the rat perfused heart.
    Hu WM; Man RY
    Br J Pharmacol; 1991 Dec; 104(4):773-5. PubMed ID: 1667284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PAF-mediated platelet adhesion to endothelial cells induced by FMLP-stimulated leukocytes.
    Hirafuji M; Shinoda H
    J Lipid Mediat; 1991 Nov; 4(3):347-51. PubMed ID: 1662550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interaction of the Paf antagonist WEB 2086 and its hetrazepine analogues with human platelets and endothelial cells.
    Korth R; Hirafuji M; Keraly CL; Delautier D; Bidault J; Benveniste J
    Br J Pharmacol; 1989 Oct; 98(2):653-61. PubMed ID: 2555017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Platelet-activating factor (PAF) receptor antagonism by WEB 2170 improves the survival of ischaemic skeletal muscle.
    Lepore DA; Knight KR; Stewart AG; Riccio M; Morrison WA
    Ann Acad Med Singap; 1995 Jul; 24(4 Suppl):63-7. PubMed ID: 8572529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.